The PR clearly states the following, "Generex has surpassed the final threshold and has completed its GMP manufacturing of its vaccine for human clinical trials, which is a key necessary component to be included in the company’s IND submission". No doubt, that is huge progress! Regardless of what happened in the distant past, it appears GNBT is slowly but surely progressing toward something "big time" for it's shareholders. GLTA!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.